ARTICLE | Clinical News
trans-ISA247: Bridging study data
July 12, 2004 7:00 AM UTC
In the single ascending-dose SAD trial in 40 patients, trans-ISA247 showed no serious adverse effects. The company plans to begin a Canadian Phase III trial to treat psoriasis by year end, and a Phase...